<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00358202</url>
  </required_header>
  <id_info>
    <org_study_id>NUR0300202A</org_study_id>
    <nct_id>NCT00358202</nct_id>
  </id_info>
  <brief_title>Cefepime vs. Ceftriaxone to Treat Nursing Home-Acquired Pneumonia</brief_title>
  <official_title>Phase 4 Study of Once-Daily Intramuscular Cefepime Versus Ceftriaxone for In-Home Treatment of Nursing Home-Acquired Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CPL Associates</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Elan Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CPL Associates</source>
  <brief_summary>
    <textblock>
      Randomized trial of nursing home residents with pneumonia to assess if intramuscular cefepime
      is a safe, efficacious, and cost-effective alternative to once daily intramuscular
      ceftriaxone for the treatment of elderly nursing home residents who develop pneumonia and do
      not require hospitalization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the efficacy, safety, and pharmacoeconomics of cefepime versus ceftriaxone.
      Double-blind study of nursing home residents &gt;60 years of age with pneumonia. Patients were
      randomized to cefepime or ceftriaxone 1 gm q24h to be administered intramuscularly. After
      three days, responding patients could be switched to oral antibiotics. Main Outcome Measures:
      clinical success, adverse events, and cost-effectiveness ratios.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2002</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total cost of all antibiotics.</measure>
    <time_frame>7-14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy, safety, and cost-effectiveness analysis of total healthcare costs.</measure>
    <time_frame>7-14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Pneumonia</condition>
  <arm_group>
    <arm_group_label>1 cefepime</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2 ceftriaxone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cefepime</intervention_name>
    <description>cefepime hydrochloride 1gm IM q24h</description>
    <arm_group_label>1 cefepime</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ceftriaxone</intervention_name>
    <description>ceftriaxone 1 gm IM q24h</description>
    <arm_group_label>2 ceftriaxone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Residents of a nursing home for &gt;=30 days who were at least 60 years of
        age and developed pneumonia not amenable to oral antibiotics while not requiring
        hospitalization, a new infiltrate on chest Xray, estimated Clcr &lt;=60 mL/min, presence of
        standard clinical criteria, signed informed consent.

        Exclusion Criteria: Allergy to cephalosporins, receipt of &gt;24 hours of an antibiotic
        (unless no improvement was evident), an existing infection due to a pathogen known
        resistant to either study drug; expected mortality within 48 hours, immunosuppression,
        hypotension or respiratory distress requiring ventilatory support, prior limited treatment
        or supportive care only directives, suspected or known Pseudomonas aeruginosa or MRSA
        infections, primary lung cancer or another malignancy metastatic to the lungs, bronchial
        obstruction or a history of post-obstructive pneumonia, or patients receiving renal
        dialysis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph A Paladino, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CPL Associates, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CPL Associates,LLC</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2006</study_first_submitted>
  <study_first_submitted_qc>July 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2006</study_first_posted>
  <last_update_submitted>October 29, 2007</last_update_submitted>
  <last_update_submitted_qc>October 29, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2007</last_update_posted>
  <keyword>intramuscular antibiotics</keyword>
  <keyword>nursing home acquired pneumonia</keyword>
  <keyword>nhap</keyword>
  <keyword>pharmacoeconomics</keyword>
  <keyword>cefepime</keyword>
  <keyword>ceftriaxone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ceftriaxone</mesh_term>
    <mesh_term>Cefepime</mesh_term>
    <mesh_term>Cephalosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

